Compile Data Set for Download or QSAR
maximum 50k data
Found 1005 with Last Name = 'kaptein' and Initial = 'a'
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM474107(Pazopanib metabolite M27 | US10858364, Compound M2...)
Affinity DataKi:  188nMAssay Description:Inhibitory activity on BTK wild type (BTK-WT) and BTK Cys481Ser mutant (BTK-C481S) was measured using the LanthaScreen assay technology from ThermoFi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.100nMAssay Description:Inhibition of recombinant full length human His-tagged BLK cytoplasmic domain expressed in baculovirus expression system using tyrosine-1 peptide as ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558092(CHEMBL4784814)
Affinity DataIC50:  0.150nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50559911(CHEMBL4744536)
Affinity DataIC50:  0.150nMAssay Description:Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lynt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM267789(4-{8-amino-3-[(3R,6S)-1-(cyclopropylcarbonyl)-6-me...)
Affinity DataIC50:  0.170nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558095(CHEMBL4752314)
Affinity DataIC50:  0.170nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558093(CHEMBL4798236)
Affinity DataIC50:  0.190nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558088(CHEMBL4751655)
Affinity DataIC50:  0.220nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50559913(CHEMBL4763873)
Affinity DataIC50:  0.260nMAssay Description:Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lynt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM267703((R)-4-(8-amino-5-deutero-3-(1-(3-methoxypropanoyl)...)
Affinity DataIC50:  0.270nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM267791(4-{8-amino-3-[(3R,6S)-1-(cyclopropylcarbonyl)-6-me...)
Affinity DataIC50:  0.280nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM267790(4-(8-amino-3-{(3R,6S)-6-methyl-1-[(3-methyloxetan-...)
Affinity DataIC50:  0.310nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM267819(4-(8-amino-3-{(3S,6S)-6-(methoxymethyl)-1-[(3-meth...)
Affinity DataIC50:  0.310nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558112(CHEMBL4799627)
Affinity DataIC50:  0.320nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558090(CHEMBL4756290)
Affinity DataIC50:  0.320nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50559912(CHEMBL4791702)
Affinity DataIC50:  0.330nMAssay Description:Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lynt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM267792(4-{8-amino-3-[(3R,6S)-6-methyl-1-propanoylpiperidi...)
Affinity DataIC50:  0.360nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM267869(4-(8-amino-3-{(3R)-1-[(3-methyloxetan-3-yl)carbony...)
Affinity DataIC50:  0.370nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Covalution Pharma

Curated by ChEMBL
LigandPNGBDBM4566(4-anilinoquinazoline deriv. 1 | CHEMBL91867 | N-{4...)
Affinity DataIC50:  0.370nMAssay Description:Inhibition of EGFRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Covalution Pharma

Curated by ChEMBL
LigandPNGBDBM50579857(CHEMBL5077776)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558109(CHEMBL4764215)
Affinity DataIC50:  0.410nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558097(CHEMBL4787427)
Affinity DataIC50:  0.410nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558107(CHEMBL4743911)
Affinity DataIC50:  0.420nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.430nMAssay Description:Inhibition of His-tagged recombinant human His-tagged full length BTK expressed in baculovirus expression system using Tyr01 peptide as substrate pre...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558094(CHEMBL4764139)
Affinity DataIC50:  0.450nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50559922(CHEMBL4759528)
Affinity DataIC50:  0.470nMAssay Description:Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lynt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Covalution Pharma

Curated by ChEMBL
LigandPNGBDBM50322823((S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahy...)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of EGFRMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of recombinant Btk after 60 minsMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM267870(4-(8-amino-3-{(3R)-1-[(3-methyloxetan-3-yl)carbony...)
Affinity DataIC50:  0.520nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558089(CHEMBL4788780)
Affinity DataIC50:  0.520nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558108(CHEMBL4783242)
Affinity DataIC50:  0.530nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50559919(CHEMBL4782725)
Affinity DataIC50:  0.540nMAssay Description:Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lynt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558091(CHEMBL4781173)
Affinity DataIC50:  0.540nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Covalution Pharma

Curated by ChEMBL
LigandPNGBDBM4567(4-anilinoquinazoline deriv. 2 | BMC163482 Compound...)
Affinity DataIC50:  0.700nMAssay Description:Irreversible inhibition of EGFRMore data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM267867(4-(8-amino-3-{(3R)-1-[(3-methyloxetan-3-yl)carbony...)
Affinity DataIC50:  0.710nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558110(CHEMBL4794031)
Affinity DataIC50:  0.740nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Covalution Pharma

Curated by ChEMBL
LigandPNGBDBM50579860(CHEMBL5076067)
Affinity DataIC50:  0.800nMAssay Description:Inhibition of EGFR T790M/L858R double mutant (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50559914(CHEMBL4792062)
Affinity DataIC50:  0.800nMAssay Description:Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lynt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCytoplasmic tyrosine-protein kinase BMX(Homo sapiens (Human))
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.800nMAssay Description:Inhibition of His-tagged recombinant full length human His-tagged BMX cytoplasmic domain expressed in baculovirus expression system using tyrosine-1 ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM267810(4-{8-amino-3-[(3S,6R)-1-propanoyl-6-(trifluorometh...)
Affinity DataIC50:  0.860nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Covalution Pharma

Curated by ChEMBL
LigandPNGBDBM50579860(CHEMBL5076067)
Affinity DataIC50:  0.900nMAssay Description:Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Covalution Pharma

Curated by ChEMBL
LigandPNGBDBM50579857(CHEMBL5077776)
Affinity DataIC50:  0.900nMAssay Description:Inhibition of EGFR T790M/L858R double mutant (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50559920(CHEMBL4794213)
Affinity DataIC50:  0.960nMAssay Description:Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lynt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetMitogen-activated protein kinase 10(Homo sapiens (Human))
Covalution Pharma

Curated by ChEMBL
LigandPNGBDBM86633(JNK-IN-8)
Affinity DataIC50:  0.980nMAssay Description:Inhibition of JNK3More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50558098(CHEMBL4751902)
Affinity DataIC50:  0.980nMAssay Description:Reversible inhibition of recombinant full length BTK (unknown origin) baculovirus infected Sf9 cells using biotinylated EQEDEPEGDYFEWLE-NH2 peptide a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50403056(CHEMBL2216827 | US10596172, Compound I-342 | US108...)
Affinity DataIC50: <1nMAssay Description:Inhibition of BtkMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50403056(CHEMBL2216827 | US10596172, Compound I-342 | US108...)
Affinity DataIC50:  1nMAssay Description:Inhibition of Btk in human Ramos cellsMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Acerta Pharma

US Patent
LigandPNGBDBM50559918(CHEMBL4756092)
Affinity DataIC50:  1nMAssay Description:Inhibition of human recombinant full length N-terminal His6-tagged BTK expressed in baculovirus infected Sf9 cells using fluorescein labeled Blk/Lynt...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Covalution Pharma

Curated by ChEMBL
LigandPNGBDBM50322823((S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahy...)
Affinity DataIC50:  1.10nMAssay Description:Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence o...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Covalution Pharma

Curated by ChEMBL
LigandPNGBDBM50029668(AZD-9291 | Osimertinib | US10085983, Compound AZD-...)
Affinity DataIC50:  1.10nMAssay Description:Inhibition of wild type EGFR (unknown origin) preincubated for 60 mins followed by substrate addition and further incubated for 60 mins in presence o...More data for this Ligand-Target Pair
Displayed 1 to 50 (of 1005 total ) | Next | Last >>
Jump to: